Navigation Links
Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
Date:5/7/2008

d's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Safe-Harbor

This press release contains forward-looking statements regarding Genzyme's future business plans including, without limitation, statements about the potential uses and benefits of Genz-112638; when final results from the Phase 2 study will be available; and future clinical trial plans and potential uses of the data from such clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the actual timing of the completion of the analysis of clinical study results; Genzyme's ability to accurately understand and predict the outcome and impact of its clinical studies related to Genz-112638; Genzyme's ability to continue to support its clinical and other development efforts related to Genz-112638; the actual efficacy and safety of Genz-112638; the outcome of discussions with regulator
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008
2. MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook
3. TeamStaff, Inc. Reports Preliminary Second Quarter 2008 Results
4. Longs Reports Preliminary March Retail Drug Store Sales
5. Preliminary Data From Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU
6. Conseco Reports Preliminary Fourth Quarter and Year-End Results
7. NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares
8. Longs Reports Preliminary February Retail Drug Store Sales
9. CRH Medical reports preliminary year end results
10. Sunrise Reports Preliminary Selected Financial and Operating Data for Fourth-Quarter 2007
11. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Colorado (PRWEB) May 26, 2015 DENVER ... industry expands and evolves, it is also experiencing many ... And like their mainstream counterparts, one major issue that ... to recycle the tons of paper and plastic that ... , “Where others see waste we see the opportunity ...
(Date:5/26/2015)... Javon Bea President and CEO Mercy Health ... quality improvement and organizational development expertise in Mercy ... and direction for the financial, budget, marketing and clinical ... and Mercy Durable Medical Equipment. , Denise has 31 ... last 20 in home care administration. In addition to ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 The professionals ... are at it again, helping local rescue pets with ... Local dentists, Kirk Kimmerling DDS, Suzanna Aguilera DMD ... Julian Peckich DVM donating 100% of proceeds from the ... fill the parking lot to help save unwanted, local ...
(Date:5/25/2015)... Author Vincent N. Cefalu, Sr., MD. has always believed that ... of them aren’t aware of many products that are detrimental ... realize the dangers of physical inactivity and the many dangerous ... exist. There is also the fact that smokers ... In “ A Doctor’s Prescription for Longevity and Survival ” ...
(Date:5/25/2015)... New York (PRWEB) May 25, 2015 ... of patented products, launches The Preventer, a home patent ... the dangers of fire. , "House fires cost the ... Scott J. Cooper, CEO and Creative Director of ... fire deaths result from homes that have no alarmed ...
Breaking Medicine News(10 mins):Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 2Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 3Health News:"Rescue Animal Cookout" Announced at Verde Pointe Professional Park on June 25, 2015 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3
... WATERTOWN, Mass., July 7 , , , WHAT: ... trial in Alzheimer,s disease patients with its, ... WHEN: Wednesday, July 15, 2009., WHERE: ... on Alzheimer,s Disease (ICAD) in Vienna, Austria., WHO: ...
... NEW BRUNSWICK, N.J., July 7 Johnson & Johnson will ... (Eastern Time) on Tuesday, July 14, 2009, to review second-quarter ... Officer, and Louise Mehrotra, Vice President, Investor Relations, will host ... may access the broadcast by visiting the Company,s website at ...
... , WILTON, Conn., July 7 Startech Environmental Corp. (OTC BB: ... its shareholders not to take any action with respect to the ... LRL Holdings LLC to purchase all of the outstanding shares of ... Startech board of directors today said that it will carefully review ...
... (Nasdaq: HMSY ) today announced that it had ... of the Governor, Division of Medicaid (DOM) to provide various ... government insurers, commercial and Medicare recoveries, Medicare Buy-In services, and ... also includes pharmacy data matches to be transmitted to pharmacies ...
... Holdings Group, Inc. (Other OTC: CTYX.PK) today announced that the Company ... June 30, 2009, on Pink Sheets. , , The ... decreasing its net loss by 50% for the second quarter of ... had a net loss of $79,679 for the second quarter of ...
... "This is a fully equipped bio-safety level 2 laboratory dedicated ... Medical Affairs for Medizone. "This new laboratory is located ... in the country and will provide a primary research and ... is now a clear path to commercialization with its lead ...
Cached Medicine News:Health News:EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease 2Health News:Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer 2Health News:Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer 3Health News:Connectyx Technologies Holdings Group, Inc. Increases Revenues by 45% and Reduces Expenses by 20% for the Second Quarter of 2009 Versus Second Quarter 2008 2Health News:Connectyx Technologies Holdings Group, Inc. Increases Revenues by 45% and Reduces Expenses by 20% for the Second Quarter of 2009 Versus Second Quarter 2008 3Health News:Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queen's University at Kingston, Ontario, Canada. 2
(Date:5/22/2015)... -- The North American dental lasers market was ... reach $90.7 million by 2019, at a CAGR of 9.2% ... of North America Dental Lasers Market for an analysis of ... and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ...   Dental lasers are specifically used in oral ...
(Date:5/22/2015)... and KING OF PRUSSIA, Pa. , ... (NHF) has awarded CSL Behring its 2015 Corporate ... commitment to advancing science and improving the care of the ... Perreault , CEO and Managing Director, CSL Limited, during the ... on May 21. "The National Hemophilia ...
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... 2010 Ambit Biosciences (Ambit), today announced ... two products AC430, a selective Janus Kinase 2 (JAK2) ... Phase I trial for AC430 is a two part, ... healthy volunteers.  AC430 will be administered orally once-daily and ...
... Mass., Dec. 20, 2010 The Center for Business Intelligence ... in Massachusetts in 2009. The honor was awarded recently to ... and The Commonwealth Institute at the Boston Park Plaza Hotel. ... Massachusetts for 2009 collectively represent over $47.5B in annual revenue ...
Cached Medicine Technology:Ambit Biosciences Initiates Two Phase I Clinical Trials 2The Center for Business Intelligence (CBI) Receives Top 100 Women-Led Businesses Award 2
... The HemoPoint H2 Hemoglobin Measurement ... determination of hemoglobin in arterial, venous, ... infants, and children in a professional ... number 3010-100 is indicated for use ...
... A dip-and-read urinalysis product available for ... systems. Clinitek® Microalbumin Strips provide albumin, ... one minute. The Clinitek® Microalbumin product ... in patients with diabetes or hypertension ...
... Thin Film technology is here! LTF™ (Layered ... rapid point-of-care test platform that is easy ... and thin as a credit card. What ... number one reason women visit their physician. ...
... The InstaCheck® multi-drug test ... simply and easily. Negative results ... few as 3 minutes; positive ... A simple, one-time urine sample ...
Medicine Products: